Global Research Antibodies Market, By Product (Reagents, Antibodies), Drug Type (Monoclonal Antibodies, Polyclonal Antibodies, ADCs, Others), Technology (Western Blotting, Flow Cytometry, ELISA, Immunohistochemistry, Immunofluorescence, Immunoprecipitation, Others), Application (Proteomics, Drug Development, Genomics), End-User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, CROs) – Industry Trends and Forecast to 2030.
Research Antibodies Market Analysis and Size
According to the American Cancer Society, over 1.9 million new cancer cases will be diagnosed in the United States in 2021. In addition, over 608,570 cancer deaths were recorded in the United States during the same year. As a result, more research antibodies will most likely be used in the development and testing of new diagnostic and therapeutic approaches for cancer prevention.
Data Bridge Market Research analyses that the research antibodies market which was USD 1178.4 billion in 2022, is expected to reach USD 1921.14 billion by 2030, at a CAGR of 6.3% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Research Antibodies Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (Reagents, Antibodies), Technology (Western Blotting, Flow Cytometry, Multiplex Immunosorbent Assay, Immunoprecipitation, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation, Other Technologies), Application (Proteomics, Drug Development, Genomics), End User (Pharmaceutical and Biotechnologies Industries, Academic and Research Institutions, Contract Research Organizations)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
General Electric (U.S.), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann La-Roche AG (Switzerland), Rockland Immunochemicals Inc. (U.S.), Johnson & Johnson private Limited (U.S.), Agilent Technologies Inc. (U.S.), Eli Lily and Company (U.S.), BD (U.S.), Danaher (U.S.), PerkinElmer Inc. (U.S.), GenScript Biotech Corporation (U.S.), Lonza (Switzerland), Bio-Techne Corporation (U.S.), Bio-Rad Laboratories Inc. (U.S.), Teva Pharmaceutical Industries Limited (Israel), Santa Cruz Biotechnology Inc. (U.S.), BioLegend Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Research antibodies are used to detect an unconjugated primary antibody, which is then used to target antigen. These products aid in the detection, measurement, and purification of proteins or biomolecules in a variety of applications such as flow cytometry, ELISA, western blotting, and immunohistochemistry.
Research Antibodies Market Dynamics
Drivers
- Increased investment in medical and health R&D
Increased investment in medical and health research and development is expected to fuel the growth of the research antibodies market. In the field of life science research, antibodies and reagents are critical components in the investigation of biological processes or disease causes through careful experimentation, observation, laboratory work, analysis, and testing. According to data published in December 2019 by the American Association for the Advancement of Science (AAAS), total investment in medical and health research in the United States increased by 6.4%. The health industry invested $129.5 billion (66.7%), followed by $43 billion (22.2%) from federal agencies and $21.7 billion (11.2%) from foundations, state and local governments, academic research institutions, and voluntary health associations. As a result, increased investment in healthcare research and development will lead to increased use of research antibodies.
- Increasing prevalence of neurodegenerative diseases
Antibodies are now one of the most important research tools for projects examining the functions of various proteins in cells. The rising prevalence of neurodegenerative diseases such as Huntington's disease, Multiple Sclerosis, and Parkinson's disease is fuelling research opportunities to better understand these conditions. Furthermore, the growing geriatric population, as well as a scarcity of chronic disease treatments, have contributed to an increase in demand for research antibodies to develop personalised medicines, cutting-edge pharmaceuticals, and novel and effective treatments.
Opportunities
- Technological advancements in the purification of antibodies
Technological advancements in antibody and reagent purification indicate opportunities for growth in the Research antibodies market during the forecast period. Genscript launched AmMag technology in 2019, a semi-automatic purification instrument that reduces the purification process from days to hours. AmMag SA was formed as a result of a licence agreement with Amgen.
Restraints/Challenges
- High cost
The research antibodies market's growth is expected to be hampered by the high cost and time required for antibody development and pricing pressure on major players.
During the forecast period, the research antibodies market is expected to face challenges from rising quality concerns and a lack of reproducible results.
This research antibodies market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the research antibodies market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on the Research Antibodies Market
There has been a significant increase in research-based activities aimed at developing effective diagnosis or therapy because of the growing number of COVID-19 cases. End-user adoption of Research antibodies is being driven by an increase in the number of research activities. The following initiatives have been launched by manufacturers and organizations: In March 2020, the Canadian government committed USD 205.5 million to coronavirus research, increasing global funding. This investment will be used to conduct research on COVID-19 medical countermeasures. As part of a global response to the COVID-19 pandemic, European governments have pledged over USD 7.67 billion (EUR 7 billion) in initial funding. The European Institute of Innovation and Technology (EIT) Health announced a USD 7.69 million (EUR 7 million) investment in COVID-19 research that will benefit 15 countries.
Recent Developments
- In October 2020, Centivac Inc, a contract research organisation, announced a strategic agreement to licence anti-covid-19 antibodies from Thermo Fisher Scientific.
Global Research Antibodies Market Scope
The Research antibodies market is segmented on the basis of product, drug type, technology, application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Reagents
- Media and sera
- Stains and dyes
- Fixatives
- Buffers
- Solvents
- Enzymes
- Probes
- Other reagents
- Antibodies
Type
- Primary antibodies
- Secondary antibodies
Form
- Monoclonal
- polyclonal
- Recombinant
Source
- Mice
- Rabbits
- Other sources
Research area
- Oncology
- Infectious diseases
- Immunology
- Neurobiology
- Stem cells
- Other research areas
Technology
- Western Blotting
- Flow Cytometry
- Multiplex Immunosorbent Assay
- Immunoprecipitation
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Other Technologies
Application
- Proteomics
- Drug Development
- Genomics
End User
- Pharmaceutical and Biotechnologies Industries
- Academic and Research Institutions
- Contract Research Organizations
Research Antibodies Market Regional Analysis/Insights
The Research antibodies market is analysed and market size insights and trends are provided by country, product, drug type, technology, application and end-user as referenced above.
The countries covered in the Research antibodies market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the research antibodies market because of increased investment in the development of structure-based drug designs, there is a greater emphasis on research projects involving proteins, associated biomolecules, and genes.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 because of an increase in genomics and proteomics research and development.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Research Antibodies Market Share Analysis
The Research antibodies market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Research antibodies market.
Some of the major players operating in the research antibodies market are:
- General Electric (U.S.)
- Merck KGaA (Germany)
- Thermo Fisher Scientific Inc. (U.S.)
- F. Hoffmann La-Roche AG (Switzerland)
- Rockland Immunochemicals Inc. (U.S.)
- Johnson & Johnson private Limited (U.S.)
- Agilent Technologies Inc. (U.S.)
- Eli Lily and Company (U.S.)
- BD (U.S.)
- Danaher (U.S.)
- PerkinElmer Inc. (U.S.)
- GenScript Biotech Corporation (U.S.)
- Lonza (Switzerland)
- Bio-Techne Corporation (U.S.)
- Bio-Rad Laboratories Inc. (U.S.)
- Teva Pharmaceutical Industries Limited (Israel)
- Santa Cruz Biotechnology Inc. (U.S.)
- BioLegend Inc. (U.S.)
SKU-